Last Price
33.20
Today's Change
+0.34 (1.03%)
Day's Change
31.22 - 33.31
Trading Volume
1,353,788
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Anthony S. Marucci M.B.A. Mr. Anthony S. Marucci M.B.A.
Full Time Employees: 160 160
IPO Date: 1986-05-15 1986-05-15
CIK: 0000744218 0000744218
ISIN: US15117B2025 US15117B2025
CUSIP: 15117B202 15117B202
Beta: 1.56 1.56
Last Dividend: 0.00 0.00
Dcf Diff: 38.21 38.21
Dcf: -5.38 -5.38
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.